Nanobiotix

NANOFR0011341205

Nanobiotix is a biotechnology company that uses nanomedicine to develop new radiotherapy techniques for cancer patients. The company is headquartered in Paris, with additional corporate offices in New York and Massachusetts.

Filings

142 filings

All Inside information63 Voting rights and capital32 Threshold crossing29 Quarterly financial information5 Earnings release4 Annual financial report4 Universal registration document2 Tender offer2

30/07/2026
Voting Rights and Shares Capital of the Company
Voting rights and capitalFR
06/07/2026
Franchissements de seuils
Threshold crossingFrench
05/06/2026
Voting Rights and Shares Capital of the Company
Voting rights and capitalFR
02/06/2026
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
Quarterly financial informationFR
02/06/2026
Nanobiotix Joins the Euronext Tech Leaders Index
Inside informationFR
26/05/2026
NANOBIOTIX Announces Closing of Global Offering
Inside informationFR
22/05/2026
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
Inside informationFR
21/05/2026
NANOBIOTIX annonce les modalites definitives de son offre globale sursouscrite a hauteur de 85 millions d’euros
Inside informationFrench
21/05/2026
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
Inside information
21/05/2026
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
Inside informationFR
21/05/2026
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
Inside informationFR
21/05/2026
Nanobiotix Announces Launch of Global Follow-On Offering
Inside informationFR
17/05/2026
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
Inside informationFR
11/05/2026
Franchissement de seuil
Threshold crossingFrench
04/05/2026
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
Inside informationFR
20/04/2026
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
Inside informationFR
07/04/2026
Voting Rights and Shares Capital of the Company
Voting rights and capitalFR
31/03/2026
DOCUMENT D'ENREGISTREMENT UNIVERSEL 2025
Universal registration documentFrenchZIP
31/03/2026
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
Annual financial reportFR
30/03/2026
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
Inside informationFR
26/03/2026
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
Inside information
26/03/2026
NANOBIOTIX publiera ses résultats financiers et opérationnels de l’exercice 2025 le 31 mars 2026
Earnings releaseFrench
25/03/2026
NANOBIOTIX Statement Regarding Recent Media Speculation
Tender offerFR
12/03/2026
Voting Rights and Shares Capital of the Company
Voting rights and capital
25/02/2026
NANOBIOTIX participera à plusieurs conférences investisseurs en mars
Inside informationFrench
17/02/2026
Voting Rights and Shares Capital of the Company
Voting rights and capitalFR
02/02/2026
Franchissement de seuils
Threshold crossingFrench
02/02/2026
Franchissement de seuils
Threshold crossingFrench
27/01/2026
Franchissement de seuils
Threshold crossingFrench
26/01/2026
Franchissement de seuils
Threshold crossingFrench
19/01/2026
Franchissement de seuils
Threshold crossingFrench
13/01/2026
Voting Rights and Shares Capital of the Company
Voting rights and capitalFR
23/12/2025
Franchissement de seuils
Threshold crossingFrench
17/12/2025
Voting Rights and Shares Capital of the Company
Voting rights and capitalFR
15/12/2025
Franchissement de seuils
Threshold crossingFrench
15/12/2025
Franchissement de seuils
Threshold crossingFrench
15/12/2025
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
Inside informationFR
05/12/2025
Franchissement de seuils
Threshold crossingFrench
28/11/2025
Franchissement de seuil
Threshold crossingFrench
24/11/2025
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
Quarterly financial information
17/11/2025
Franchissement de seuil
Threshold crossingFrench
17/11/2025
Franchissements de seuil
Threshold crossingFrench
14/11/2025
Voting Rights and Shares Capital of the Company
Voting rights and capitalFR
13/11/2025
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
Inside informationFR
13/11/2025
Franchissement de seuil
Threshold crossingFrench
13/11/2025
Franchissement de seuil
Threshold crossingFrench
13/11/2025
Franchissement de seuil
Threshold crossingFrench
11/11/2025
NANOBIOTIX to Participate in Jefferies London Healthcare Conference
Inside informationFR
04/11/2025
Franchissement de seuils
Threshold crossingFrench
03/11/2025
NANOBIOTIX to Participate in Investor Conferences the Week of November 10th
Inside informationFR
31/10/2025
NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
Inside informationFR
24/10/2025
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control
Inside informationFR
15/10/2025
Voting Rights and Shares Capital of the Company
Voting rights and capitalFR

About

ISIN: FR0011341205
Ticker: NANO
LEI: 969500667RSYIH8YL895
Founded: 2003
Country of registration: FR
Last filing: 30/07/2026, 22:15

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive